Introduction Biological fluids are routine samples for diagnostic testing and monitoring.
Blood samples are typically measured because of their moderate invasive collection and …

IgA nephropathy (IgAN) is the most common primary glomerulonephritis, frequently leading
to end-stage renal disease, as there is no disease-specific therapy. IgAN is diagnosed from …

Urine has become one of the most attractive biofluids in clinical proteomics as it can be
obtained non-invasively in large quantities and is stable compared with other biofluids. The …

Diabetic nephropathy (DN) is a progressive kidney disease, a well-known complication of
long-standing diabetes. DN is the most frequent reason for dialysis in many Western …

Biomarkers are the measurable changes associated with physiological or
pathophysiological processes. Urine, unlike blood, lacks mechanisms for maintaining …

Mass spectrometry platforms have attracted a lot of interest in the last 2 decades as profiling
tools for native peptides and proteins with clinical potential. However, limitations associated …

Urine is a readily and noninvasively obtainable body fluid. Mass spectrometry (MS)-based
proteomics has shown that urine contains thousands of proteins. Urine is a potential source …

A limitation of proteomic methods with respect to their clinical applicability is the lack of
possibilities to directly deduce the amount of a protein or peptide from a particular mass …

Urinary biomarkers for diabetes, diabetic nephropathy, and nondiabetic proteinuric renal
diseases were sought. For 305 individuals, biomarkers were defined and validated in …

Background. Chronic kidney disease (CKD) progression is currently assessed by a decline
in estimated glomerular filtration rate (eGFR) and/or an increase in urinary albumin excretion …